Skip to main content

Table 2 Characteristics of included studies for neoadjuvant chemotherapy

From: Diffusion-weighted imaging in monitoring the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis

Study Year No. of cases Classification of pathologic response Definition of pCR NACT regimens Surgery after NACT
Agarwal 2017 38 Miller-Payne Miller-Payne grade V CEF, CAF, CEF + DE, DE, DC + Herceptin, DEC Modified radical mastectomy or wide local excision
Atuegwu 2013 28 – No residual invasive cancer in the breast or lymph nodes AC + taxol, Taxotere, Taxol + cisplatin ± everolimus, Trastuzumab +carboplatin + ixabepilone, Trastuzumab, and lapatinib NR
Belli 2011 51 Mandard’s TRG criteria TRG 1 FEC, AT, TAC, and TC ± carboplatinum or trastuzumab Surgery
Bufi 2014 225 Mandard’s TRG criteria TRG 1 Doxorubicin and cyclophosphamide, and taxanes-based regimens Breast-conserving and nipple sparing surgery; Surgical excision
Bufi 2015 225 Mandard’s TRG criteria TRG 1 Doxorubicin, taxane, and cyclophosphamide-based regimens Breast-conserving and nipple sparing surgery; Surgical excision
Che 2016 36 Miller-Payne Miller-Payne grade V Paclitaxel with epirubicin or paclitaxel with carboplatin Breast-conserving surgery with axillary nodal clearance or modified radical mastectomy.
Fangberget 2010 31 – Absence of invasive cancer 5-fluoro-uracil, epirubicin and cyclophosphamide Surgery
Fujimoto 2013 56 Japanese Breast Cancer Society criteria Necrosis or disappearance of all tumor cells Adriamycin and cyclophosphamide, paclitaxel, 5-fluorouracil, epirubicin, and cyclophosphamide, paclitaxel Lumpectomy or mastectomy
Li 2011 32 – Absence of invasive cancer on breast tumor and lymph nodes Docetaxel and epirubicin Breast-conserving surgery or modified radical mastectomy
Li 2015 42   No invasive tumor in the breast DOX + Cyc + Tax, Cis/Tax±RAD001, Tra + Car, Tra/Car/Her, Tax Mastectomy or lumpectomy
Luo 2014 71 Miller-Payne Miller-Payne grade V NR NR
Mani 2013 28 – No residual tumor in the breast or lymph nodes Adriamycin/cytoxan, taxol/trastuzumab; docetaxel, carboplatin, and trastuzumab; or lapatinib and trastuzumab Surgery
Park 2010 53 – Absence of recognizable invasive tumor cells (DCIS may have been present) Docetaxel and doxorubicin with granulocyte colony–stimulating factor Modified radical mastectomy or breast-conserving surgery
Park 2011 34 – No residual malignancy and no sign of cancer cells; no residual invasive cancer and DCIS present Doxorubicin and docetaxel; paclitaxel, gemcitabine and trastuzumab Modified radical mastectomy or breast-conserving surgery
Richard 2013 118 Chevalier-Sataloff classifications Chevalier class 1, Sataloff A Epirubicin and cyclophosphamide, docetaxel; epirubicin and cyclophosphamide, trastuzumab Mastectomy or breast-conservative surgery
Sharma 2009 56 – No residual tumor CEF; PþE NR
Shin 2012 90 – No residual tumor or absence of invasive cancer, but presence of DCIS Doxorubicin and cyclophosphamide; cyclophosphamide and docetaxel; adriamycin plus docetaxel; 5-fluorouracil, epirubicin and cyclophosphamide; trastuzumab plus paclitaxel Surgery
Weis 2015 33 – No residual tumor in the breast or nodes Paclitaxel, carboplatin, and trastuzumab; doxorubicin and cyclophosphamide, paclitaxel; cisplatin and paclitaxel ± everolimus NR
Woodhams 2010 69 – No residual disease or no invasive cancer or DCIS present Anthracycline and cyclophosphamide, paclitaxel Quadrantectomy or mastectomy
Xu 2017 174 – No residual tumor in the breast or nodes Cyclophosphamide + epirubicin and tatotere NR
  1. Miller-Payne grade V, showed complete disappearance of malignant cells at the site of tumor with only vascular fibroelastotic stroma seen with macrophages; TRG 1, complete regression, absence of residual tumor cells; Chevalier class 1, disappearance of all tumors on either macroscopic or microscopic assessment; Sataloff A, total or near total therapeutic effect; CEF, cyclophosphamide epirubicin 5-Fluorouracil; CAF cyclophosphamide adriamycin 5-fluorouracil; DE, docetaxel epirubicin; DC, docetaxel cisplatin; DEC, docetaxel epirubicin cisplatin; FEC, fluorouracil + epirubicin + cyclophosphamide; AT, doxorubicin + taxanes; TAC, taxanes + doxorubicin + cyclophosphamide; TC, taxanes + cyclophosphamide; Dox, doxorubicin; Cyc, cyclophosphamide; Cis, cisplatin; PþE, paclitaxel and epirubicin; NR, not reported
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us